AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15746784 — intervention group
Group type: COMPARATOR
Intervention: Clamp crushing group (n = 41)
Number of subjects: 82
Study 12756602 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) administered to 91 patients in the AG group
Number of subjects: 139
Study 12756602 — intervention group
Group type: COMPARATOR
Intervention: Not treated with ACEI/ARB in the NON-AG group (48 patients)
Number of subjects: 139
Study 10566921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 5% in normal saline (Group D)
Number of subjects: 119
Study 10566921 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group NS)
Number of subjects: 119
Study 8552700 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 0
Study 1845926 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta 1/beta 2-antagonist)
Number of subjects: 47
Study 1845926 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-antagonist)
Number of subjects: 47
Study 1845926 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker (control)
Number of subjects: 47
Study 6352642 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 59
Study 6352642 — intervention group
Group type: COMPARATOR
Intervention: cefazolin and tobramycin
Number of subjects: 59
Study 31883703 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab (300 mg SC injection) at 5 seconds
Number of subjects: 50
Study 31883703 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab (300 mg SC injection) at 15 seconds
Number of subjects: 50
Study 31883703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SC injection into abdomen)
Number of subjects: 50
Study 31883703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SC injection into thigh)
Number of subjects: 50
Study 31883703 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab (300 mg SC injection)
Number of subjects: 50
Study 31828274 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan‐Meier curve analysis for survival rate
Number of subjects: 279
Study 31828274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analysis
Number of subjects: 279
Study 27430594 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI1: 15 min at 9 °C
Number of subjects: 60
Study 27430594 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI2: 15 min at 14 °C
Number of subjects: 60
Study 27430594 — intervention group
Group type: COMPARATOR
Intervention: CG: control group
Number of subjects: 60
Study 25138171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab + Docetaxel
Number of subjects: 808
Study 25138171 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Trastuzumab + Docetaxel
Number of subjects: 808
Study 23535882 — intervention group
Group type: EXPERIMENTAL
Intervention: SpineCor brace treatment
Number of subjects: 90
Study 23535882 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy only (Control)
Number of subjects: 90
Study 21312297 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (9.5 mg/24 h)
Number of subjects: 782
Study 21312297 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (12 mg/day)
Number of subjects: 782
Study 21312297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 782
Study 19767804 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic sports drink containing caffeine (6.4 g carbohydrate and 16 mg caffeine per 100 mL)
Number of subjects: 20
Study 19767804 — intervention group
Group type: COMPARATOR
Intervention: No-energy, flavour-matched placebo drink
Number of subjects: 20
Study 17295721 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned cues of monetary reward
Number of subjects: 56
Study 17295721 — intervention group
Group type: COMPARATOR
Intervention: Conditioned cues of nonreward
Number of subjects: 56
Study 14504190 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated quality improvement program to increase CRC screening
Number of subjects: 36
Study 14504190 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 36
Study 10803937 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (300 microg or 480 microg subcutaneously for 2 days prior to and up to 7 days after surgery)
Number of subjects: 20
Study 10803937 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (n=27)
Number of subjects: 20
Study 9092955 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 400 mg/day
Number of subjects: 0
Study 9092955 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 600 mg/day
Number of subjects: 0
Study 9092955 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 800 mg/day
Number of subjects: 0
Study 9092955 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at all three dosages
Number of subjects: 0
Study 9092955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8244132 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe treatment
Number of subjects: 101
Study 8244132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 101
Study 3533562 — intervention group
Group type: EXPERIMENTAL
Intervention: bufuralol (60 mg)
Number of subjects: 22
Study 3533562 — intervention group
Group type: COMPARATOR
Intervention: propranolol (160 mg)
Number of subjects: 22
Study 3533562 — intervention group
Group type: COMPARATOR
Intervention: pindolol (10 mg)
Number of subjects: 22
Study 3533562 — intervention group
Group type: EXPERIMENTAL
Intervention: bufuralol (30-60 mg bd)
Number of subjects: 22
Study 3533562 — intervention group
Group type: COMPARATOR
Intervention: propranolol (40-80 mg bd)
Number of subjects: 22
Study 31255349 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP) - 35% protein (1.34 g/kg/day)
Number of subjects: 73
Study 31255349 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein diet (SP) - 18% protein (0.75 g/kg/day)
Number of subjects: 73
Study 29916060 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual faces associated with a high proportion of congruent trials
Number of subjects: 0
Study 27720066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 2453
Study 27720066 — intervention group
Group type: COMPARATOR
Intervention: Other treatments
Number of subjects: 2453
Study 27720066 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis (both studies)
Number of subjects: 2453
Study 27720066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (CAMELOT)
Number of subjects: 2453
Study 27720066 — intervention group
Group type: EXPERIMENTAL
Intervention: BPV
Number of subjects: 2453
Study 27720066 — intervention group
Group type: COMPARATOR
Intervention: Mean SBP
Number of subjects: 2453
Study 24763706 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation in HCM patients
Number of subjects: 51
Study 24763706 — intervention group
Group type: COMPARATOR
Intervention: Mid-posterior wall thickness
Number of subjects: 51
Study 24763706 — intervention group
Group type: COMPARATOR
Intervention: Infero-posterior wall thickness
Number of subjects: 51
Study 22419562 — intervention group
Group type: EXPERIMENTAL
Intervention: Seldinger technique
Number of subjects: 412
Study 22419562 — intervention group
Group type: COMPARATOR
Intervention: Modified Seldinger technique
Number of subjects: 412
Study 20185740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus weight loss (10 mg/day)
Number of subjects: 25
Study 20185740 — intervention group
Group type: COMPARATOR
Intervention: Weight loss alone
Number of subjects: 25
Study 18600034 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (daily dose = 40 mg)
Number of subjects: 9
Study 18600034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15750375 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertigoheel (n=87)
Number of subjects: 170
Study 15750375 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba (n=83)
Number of subjects: 170
Study 12214830 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal drainage and peritonization (Group B)
Number of subjects: 100
Study 12214830 — intervention group
Group type: COMPARATOR
Intervention: No peritonization and no drainage (Group A)
Number of subjects: 100
Study 10379635 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.1 U x kg‐body‐weight(‐1))
Number of subjects: 25
Study 10379635 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (0.1 U x kg‐body‐weight(‐1))
Number of subjects: 25
Study 8682965 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 1% topical solution
Number of subjects: 40
Study 8682965 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 40
Study 1762810 — intervention group
Group type: COMPARATOR
Intervention: conventional continuous stimulation (70 Hz)
Number of subjects: 14
Study 1762810 — intervention group
Group type: EXPERIMENTAL
Intervention: burst stimulation (90 Hz)
Number of subjects: 14
Study 1762810 — intervention group
Group type: EXPERIMENTAL
Intervention: high-rate frequency modulation (90 Hz to 55 Hz)
Number of subjects: 14
Study 1762810 — intervention group
Group type: EXPERIMENTAL
Intervention: low-rate frequency modulation (60 Hz to 20 Hz)
Number of subjects: 14
Study 6751705 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg xipamide daily for 7 days
Number of subjects: 15
Study 6751705 — intervention group
Group type: COMPARATOR
Intervention: 40 mg frusemide daily for 7 days
Number of subjects: 15
Study 6751705 — intervention group
Group type: EXPERIMENTAL
Intervention: xipamide
Number of subjects: 15
Study 6751705 — intervention group
Group type: COMPARATOR
Intervention: frusemide
Number of subjects: 15
Study 31907019 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 1320
Study 31907019 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplementation
Number of subjects: 1320
Study 31907019 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity plus multi-micronutrient supplementation
Number of subjects: 1320
Study 31907019 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1320
Study 29314376 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral D-amphetamine
Number of subjects: 98
Study 29314376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 28328713 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Strength Training (n = 16)
Number of subjects: 44
Study 28328713 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Strength Training (n = 16)
Number of subjects: 44
Study 28328713 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n = 12)
Number of subjects: 44
Study 26031764 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (1 mg/day)
Number of subjects: 450
Study 26031764 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Minoxidil
Number of subjects: 450
Study 26031764 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medication (Finasteride + 5% Minoxidil)
Number of subjects: 450
Study 24268976 — intervention group
Group type: EXPERIMENTAL
Intervention: High flexion prosthesis
Number of subjects: 278
Study 24268976 — intervention group
Group type: COMPARATOR
Intervention: Standard prosthesis
Number of subjects: 278
Study 24268976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 278
Study 23057323 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose beta-conglycinin (4.6g in 8 test tablets daily)
Number of subjects: 100
Study 23057323 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose beta-conglycinin (2.3g in 4 test tablets daily)
Number of subjects: 100
Study 23057323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 tablets containing no beta-conglycinin)
Number of subjects: 100
Study 19197821 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG) alone
Number of subjects: 208
Study 19197821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Hysterosalpingography (HSG) and Sonohysterography (SHG)
Number of subjects: 208
Study 17698897 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE therapy)
Number of subjects: 19
Study 17698897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15774788 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2 weekly for 9 cycles)
Number of subjects: 54
Study 15774788 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2 every 2 weeks for 4 cycles)
Number of subjects: 54
Study 12361192 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI + NAC (600 mg t.i.d.)
Number of subjects: 18
Study 12361192 — intervention group
Group type: COMPARATOR
Intervention: ACEI only
Number of subjects: 18
Study 9825365 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of AF episodes
Number of subjects: 25
Study 9825365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-portion of AF episodes
Number of subjects: 25
Study 9825365 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of AF episodes
Number of subjects: 25
Study 9825365 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset to mid-portion comparison
Number of subjects: 25
Study 9825365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-portion to termination comparison
Number of subjects: 25
Study 8303575 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily fractionation schedules of 1.2 Gy/fraction, 1.4 Gy/fraction, and 1.6 Gy/fraction with an interfraction interval of four to six hours.
Number of subjects: 0
Study 8303575 — intervention group
Group type: EXPERIMENTAL
Intervention: TDFt and TSD concepts
Number of subjects: 0
Study 8303575 — intervention group
Group type: EXPERIMENTAL
Intervention: LQ concept
Number of subjects: 0
Study 2640159 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention condition
Number of subjects: 0
Study 2640159 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention condition
Number of subjects: 0
Study 6995617 — intervention group
Group type: EXPERIMENTAL
Intervention: SRELAX (Transcendental Meditation)
Number of subjects: 41
Study 6995617 — intervention group
Group type: EXPERIMENTAL
Intervention: NSRELAX (Placebo control, identical training without a mantra)
Number of subjects: 41
Study 6995617 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 41
Study 30409443 — intervention group
Group type: EXPERIMENTAL
Intervention: MV-CHIK (5×10^4 or 5×10^5 50% tissue culture infectious dose)
Number of subjects: 263
Study 30409443 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 263
Study 27889312 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 888
Study 27889312 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine-CR
Number of subjects: 888
Study 26475016 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Beginning Initiative (intervention group)
Number of subjects: 3002
Study 26475016 — intervention group
Group type: COMPARATOR
Intervention: Standard health facility referral (control group)
Number of subjects: 3002
Study 23646470 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Qushi Recipe (YQR), one dose daily for eight weeks
Number of subjects: 40
Study 23646470 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine 60 mg, three times a day for eight weeks
Number of subjects: 40
Study 21280171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) and glycemic load (GL) diets
Number of subjects: 23
Study 21280171 — intervention group
Group type: COMPARATOR
Intervention: Control diets (not specified)
Number of subjects: 23
Study 19736635 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of warfarin therapy
Number of subjects: 168
Study 19736635 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of warfarin therapy
Number of subjects: 168
Study 17844693 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 80
Study 17844693 — intervention group
Group type: COMPARATOR
Intervention: Antisnake venom (ASV) and other routine measures (Control group)
Number of subjects: 80
Study 16354711 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15-30 mg elemental zinc daily for 14 days)
Number of subjects: 280
Study 16354711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 280
Study 16354711 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 280
Study 16354711 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study 14614169 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving during the year before the patient's death
Number of subjects: 217
Study 10709819 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 56
Study 10709819 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TXA) 10 g over 20 minutes before sternotomy
Number of subjects: 56
Study 8755849 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc parameters (ZnE, ZnS, ZuU)
Number of subjects: 31
Study 1928856 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl 3 micrograms.kg‐1.h‐1 (Group I)
Number of subjects: 12
Study 1928856 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of fentanyl 1 microgram.kg‐1.h‐1 and enflurane 1.2 +/‐ 0.3 vol % (Group II)
Number of subjects: 12
Study 6811475 — intervention group
Group type: EXPERIMENTAL
Intervention: High-ascorbate; average survival 246 days (55 patients)
Number of subjects: 130
Study 6811475 — intervention group
Group type: EXPERIMENTAL
Intervention: High-ascorbate; average survival 1550 days (3 patients still alive)
Number of subjects: 130
Study 6811475 — intervention group
Group type: EXPERIMENTAL
Intervention: High-ascorbate; average survival 115 days (6 patients)
Number of subjects: 130
Study 6811475 — intervention group
Group type: COMPARATOR
Intervention: Control; average survival 48 days (19 patients)
Number of subjects: 130
Study 31813632 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and water
Number of subjects: 58
Study 31813632 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable wet wipes
Number of subjects: 58
Study 29890377 — intervention group
Group type: EXPERIMENTAL
Intervention: SDI-T
Number of subjects: 64
Study 29890377 — intervention group
Group type: EXPERIMENTAL
Intervention: SDI-T + AL
Number of subjects: 64
Study 29890377 — intervention group
Group type: EXPERIMENTAL
Intervention: SDI-T + D
Number of subjects: 64
Study 26962727 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 3428
Study 26962727 — intervention group
Group type: EXPERIMENTAL
Intervention: amodiaquine-artesunate
Number of subjects: 3428
Study 26962727 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 3428
Study 26962727 — intervention group
Group type: EXPERIMENTAL
Intervention: mefloquine-artesunate
Number of subjects: 3428
Study 24033611 — intervention group
Group type: COMPARATOR
Intervention: Two-step strategy (INT2)
Number of subjects: 39
Study 24033611 — intervention group
Group type: COMPARATOR
Intervention: One-step strategy (INT1)
Number of subjects: 39
Study 22048929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reconciliation
Number of subjects: 81
Study 22048929 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital practice (Control)
Number of subjects: 81
Study 20455619 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline telephone counseling for smoking cessation; details on dosage and duration not available.
Number of subjects: 0
Study 18195316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital sign intervention (documenting smoking status as a routine vital sign)
Number of subjects: 6729
Study 18195316 — intervention group
Group type: COMPARATOR
Intervention: Control practices (no systematic tobacco screening or identification system)
Number of subjects: 6729
Study 18195316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital sign intervention
Number of subjects: 6729
Study 18195316 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 6729
Study 12440177 — intervention group
Group type: EXPERIMENTAL
Intervention: forced diuresis with i.v. crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure was < 20 mmHg), and low dose dopamine
Number of subjects: 98
Study 12440177 — intervention group
Group type: COMPARATOR
Intervention: intravenous crystalloid and matching placebos
Number of subjects: 98
Study 10338174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 16
Study 10338174 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 16
Study 7573992 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled infusion of alfentanil (CCiA)
Number of subjects: 20
Study 7573992 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled administration of morphine (PCAM)
Number of subjects: 20
Study 1938446 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral catheter
Number of subjects: 75
Study 1938446 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic catheter
Number of subjects: 75
Study 7128131 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogens combined with ethinyl estradiol (EE)
Number of subjects: 0
Study 7128131 — intervention group
Group type: COMPARATOR
Intervention: Standardized dose of ethinyl estradiol
Number of subjects: 0
Study 30474401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelike baby doll intervention (three, 30-minute, individual, non-facilitated sessions per week)
Number of subjects: 35
Study 30474401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelike baby doll intervention
Number of subjects: 35
Study 30474401 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 28625806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 28625806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25875387 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 0